Neuropsychiatric Drug Development Summit Boston
When:
Tuesday, Jul 23, 2019 8:00a -
Thursday, Jul 25, 2019 4:30p
Tuesday, Jul 23, 2019 8:00a -
Thursday, Jul 25, 2019 4:30p
Where:
Wyndham Boston Beacon Hill
5 Blossom Street
Boston, MA 02114
Admission:
$4396
Categories:
Lectures & Conferences
Event website:
https://go.evvnt.com/389254-3?pid=5248
With the huge unmet clinical need in neuropsychiatry and despite multiple approved pharmaceuticals available, the development of the next generation of neuropsychiatric drugs is essential.
Historically, drug development within neuropsychiatry has been stifled for decades by a lack of scientific progress in the neuropsychiatric field combined with costly and challenging clinical trials.
The abundance of excitement and scientific progress in the field – especially with the recent approval of esketamine – will be captured at the NPD summit, as well as unravelling the complexities of developing truly transformative neuropsychiatric drugs.
With 70+ of the field’s thought-leaders uniting from around the world, NPD summit will be your opportunity to not only gather the latest scientific insights but to discuss, in depth, the challenges that have been stifling the progress of neuropsychiatric drug development such as translatable models, biomarkers and looking to target neuropsychiatry symptomatically.
Join us at the NPD summit to stride towards developing neuropsychiatric drugs to truly transform patient quality of care.
Book early to avoid disappointment.
URLs:
Brochure https://go.evvnt.com/389254-0?pid=5248
Tickets https://go.evvnt.com/389254-1?pid=5248
Prices:
Gold: Conference and 3 workshops: USD 4396.0,
Silver: Conference and 2 workshops: USD 3897.0,
Bronze: Conference and 1 workshop: USD 3398.0,
Conference only: USD 2799.0,
Workshop only: USD 699.0
Speakers: Al Robichaud, Chief Scientific Officer, Sage Therapeutics, Andreas Meier, Senior Medical Director, Ophthalmology, Pain and New Indications, Biogen, Alan Schatzberg, Professor, Psychiatry and Behavioral Sciences, Stanford University, Bruce Kimmel, Chief Executive Officer, Vidrio Technologies, Christopher Missling, Chief Executive Officer, Anavex Life Sciences, Daniel Hoeppner, Associate Director, Astellas, Elise Robinson, Assistant Professor, Harvard University, Eric Schaeffer, Senior Director, Neuroscience Innovation, Johnson andJohnson, George Papakostas, Scientific Director, Massachusetts General Hospital, Gopi Shanker, Director, Head of Psychiatry, Novartis, James Cassella, Chief Development Officer, Concert Pharmaceuticals , Jason Uslaner, Executive Director, Neuroscience, Merck, Joris Van Dam, Executive Director, Head of Digital Therapeutics, Novartis, Kevin Sanders, Global Development Lead Autism, Roche, Laura Corradini, Deputy Global Head Business Development and Licensing, CNS, Boehringer Ingelheim, Sean Smith, Executive Director, Neuroscience Discovery, Merck, Seth Hopkins, Executive Director, Translational Medicine, Sunovion, Shil Patel, Vice President, Codiak BioSciences, Stevin Zorn, President and CEO, MindImmune Therapeutics Inc, Sylvain Celanire, Chief Executive Officer, PRAGMA Therapeutics
